REVISED NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDELINES ON THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION

That this House welcomes the change in draft guidance from the National Institute for Health and Clinical Excellence (NICE) on the treatment of wet age-related macular degeneration through the prescription of Lucentis; notes with concern that its additional proposal to ration patients to 14 injections of Lucentis paid for by the NHS would deny further treatment to those unable to afford it privately; and calls on NICE to reconsider its recommendations on treatment using the drug Macugen.